The article discusses views and recommendations of the World Marrow Donor Association concerning ethical issues related to the donation of hematopoietic stem cell products with respect to recruitment, evaluation, workup, and follow-up of unrelated donors. Particular emphasis is placed upon commitment of individual donors, in particular with respect to the needs of patients to find HLAmatched donors, who may be asked to donate stem cell and other cell products more than once for given patients.
transplantation
The World Marrow Donor Association (WMDA) is concerned with exchange of bone marrow and other forms of hematopoietic stem cells from healthy volunteer residents in one country for transplantation to patients residing in another country. During the last few years, requests for international donation of cell preparations other than marrow, such as growth factor-stimulated peripheral blood stem cells, peripheral blood lymphocytes, whole blood, and platelets have increased. As a consequence, the same donor may be asked to donate two different cell preparations separated by months to years in time to the same patient. The second request may occur after the donor and recipient have been identified to each other.
The requests for multiple donations of various types of cell products from a given donor have raised questions about the ethical and medical implications of the use of donors originally recruited solely as bone marrow donors. It is also essential to establish a balance between a donor's commitment and a patient's needs. The following recommendations, written by the WMDA Ethics Working Group and approved by the WMDA Board, are aimed at establishing a uniform practice and policy, which protects the donor's rights as well as the patient's needs, and at the same time is in accordance with common ethical standards.
General ethical considerations
The following issues are relevant for the standards and recommendations concerning donor commitment:
1. donor autonomy and integrity; 2. right to participate and right to 'choose' a volunteer; 3. donor, patient, transplant center, and donor center/ registry expectations; 4. obligation; 5. commitment; 6. eligibility.
Donor autonomy, integrity, and the right to participate vs right to choose volunteers
Autonomy is the self-governing and independent function of an individual. Integrity represents the completeness and wholeness of an individual. Well being, honesty, and sincerity are other words to describe integrity.
Patient autonomy is an ethical concept that is well established and legally protected. In contrast, autonomy in the context of the voluntary donation has been less discussed. It is, therefore, important to emphasize that any volunteer donor who is asked to donate any kind of cell or tissue samples is protected by his/her autonomy. Autonomy ensures that the donor's well being and integrity are maintained and that the donor is fully informed about the consequences, pertaining to both donor and patient, of every act during the testing and donation process. It is important that the donor center/registry understands and respects the donor's rights, integrity, and autonomy at every stage of donor evaluation. It is as important that the transplant center understands and respect that the donor center/registry cannot violate the donor's autonomy. Thus, no pressure must be placed on the involved donor or donor center/registry.
The donor is asked to subscribe a written informed consent to verify the intention to proceed to stem cell donation. A written informed consent should cover:
1. what the donor has consented to; 2. clarify the donor's right to withdraw at any time, including during the patient's pretransplant conditioning period;
3. describe the possible consequences of donor withdrawal or donor risk behavior; 4. indicate how the donor was counseled.
As mentioned, the donor is allowed to withdraw at any time, including the period while the patient is being conditioned. The donor is not obligated to reveal the reasons for withdrawal. In case of withdrawal, the donor's decision must be respected, the donor must not be forced in any way to reconsider the withdrawal by legal, economical, moral, emotional or other means, and the donor must not be made legally responsible for any consequences her/his withdrawal have on the patient. It is the responsibility of the transplant center to outline for the patient the nature of the donor's consent.
On the other hand, the donor's autonomy does not include a right to donate. If the transplant center or the donor center/registry chooses to proceed with another donor, the donor must accept the decision. This may occur with the identification of a second donor with a better HLA match, ABO compatibility, etc, or in cases where the donor is medically ineligible to donate. Further, a donor center/ registry carrying out a recruitment drive or collecting blood samples for HLA typing from a given donor has the right to 'choose' those who will be included as volunteer donors. For example, a center may exclude individuals who are within a predefined risk group, donors who appear to be physically or mentally unfit, or donors who are reserved for other purposes. Thus, the donor's autonomy protects the donor's right to choose to say 'yes' or 'no', as well as maintaining the donor's well being/integrity; however, the donor does not have the right to donate hematopoietic stem cells to a given patient. The donors have the right to maintain their autonomy just as the donor center/registry has the responsibility to exclude, in a timely fashion, any donor who may not be best fit to participate in the various procedures. This exclusion process should be an integrated part of the information provided to the donor as early as the recruitment phase.
The donor center/registry must ensure the protection of the donor's confidentiality and anonymity from the time of recruitment to stem cell donation. A decision by the donor to withdraw during the final stages of the donation may be detrimental to the patient. It is, therefore, a goal for a transplant center and donor center/registry to avoid a situation where a donor withdraws from the procedure at a critical time. To avoid detrimental withdrawal, the donor center/registry should do whatever possible to identify, as early as possible, problems or doubts that might interfere with the donor's ability to donate.
Expectations
When a donor is recruited by a donor center/registry, the donor expects to be considered as a reliable donor. Thus, to avoid false impressions of reliability and expectations, unfit volunteers should be excluded before they enter the donor center/registry.
Secondly, when a donor is contacted for further evaluation for a given patient, the donor's expectations are renewed. In addition to the donor's expectations, the donor center/registry and also have the transplant center expectations that the donor has maintained altruism, that the donor has not entered any risk group, and that the donor is still healthy and fit. The patient has high expectations that the search process per se will be successful and that any potential donor will maintain eligibility and altruism. It is therefore very important that the donor center/registry ensures that the donor obtains an objective understanding of what is requested, what a given protocol may require, and an estimate of the chance of being selected for further steps in the donation process. The education process must be such that a donor cancellation, for any reason, is not disastrous or depressing, but rather easily understandable and acceptable to the donor.
As the donor progresses to the final stages in the donation process ('workup'), the donor's as well as the transplant center's expectations are raised to an even higher level. The patient, of course, has the highest expectations. Any divergence from the planned schedule and progress will likely be stressful to all individuals involved. It is the donor center/registry's responsibility to promote good communication, trust, and understanding with the donor, so that the donor can cope with whatever event that may occur. This is true for the transplant center as well when communicating with the patient.
Obligations
The donor's feeling of obligation towards the needs of the patient probably varies among individual donors and at different stages of donor evaluation. The donor's feeling of obligation may be limited at the initial contact to obtain blood for further HLA typing (eg confirmatory typing), but may be extensive at the work-up stage prior to cell donation. A certain level of obligation is probably advantageous for all involved, but it must not dominate the donor and donor center/registry decisions. Further, the donor may be eager to become involved beyond the donor's capabilities, and expand altruism beyond what is reasonable. It is the responsibility of the donor center/registry to adjust the donor's feeling of obligation to a reasonable level that does not jeopardize the donor's well being.
There are probably several factors of psychological and emotional nature that affect a donor's feeling of obligation. The donor center/registry should be aware of these factors. A feeling of obligation is established when a given donor is contacted by the donor center/registry. A particular bond may arise when a patient contacts the donor directly, especially when the donor and the patient become acquainted after an earlier donation. The donor's feeling of obligation depends upon the information received and empathy for the patient. The donor center/registry can influence the donor's engagement through the information provided, including how requests from the transplant center are handled and by introducing the patient to the donor. Thus, 'regulation' of the donor's obligation is the donor center/registry's responsibility. Again, it is important that the donor center/registry informs the donors about their rights and limitations, ensures that the donor fully understands the consequences of each decision, and ensures that the donor's feelings of obligation are built upon objective, nonbiased, and thorough information.
It is important that the donor center/registry is not coercive when addressing a donor during workup for a donation. Thus, it is recommended that the donor center/ registry should not inform a donor about the patients' diagnosis, gender, age, and similar kinds of facts. The donor should, however, be informed about what may be expected with regard to stem cell collection and specific protocol requirements. The donor should also be informed about whether the protocol is established or experimental. Finally, general information about the prognosis of the patient may be given with great caution.
Since the vast majority of donors were originally recruited as volunteer 'bone marrow donors' only, several questions of medical, social, legal, economical, and ethical nature become evident when a transplant center asks for donation of a cell product other than bone marrow. Such cell products include hematopoietic stem cells harvested from the peripheral blood after 'stem cell mobilization', lymphocytes, buffy coat cells, whole blood, platelets, and other cells used for ex vivo manipulation. For instance, when a 'bone marrow donor' is asked to donate lymphocytes, one takes advantage of the fact that the donor happens to be in a registry of HLA-typed individuals, but, strictly speaking, the registry was generated for other purposes. In fact, this request may not be allowed under national law in some countries, and a donor would have every right to complain about misuse of personal data. On the other hand, it is very likely, particularly if the 'bone marrow donor' was recruited from a blood bank, that the donor would react positively to additional types of requests.
To minimize problems related to requests for other types of cell donation, the following should be considered:
1. At new donor recruitment drives, new recruitment brochures and other donor informational material should contain information about the alternative types of donation, and the volunteers should consent to be regarded as donors for all cell types mentioned. 2. Since it is difficult and costly to contact donors already in a donor pool and ask for additional consent to volunteer for other types of cell donation, every 'bone marrow' donor who is activated for a given patient should be informed about these possibilities at the first opportunity.
If the donor, at any step in the process, restricts himself to only one or a few types of cell donation, the transplant center should immediately be informed and the donor's decision should be respected.
Commitment
Commitment has a two-fold meaning when it pertains to donation. First, it implies the donor's decision to fulfill a given task, such as stem cell donation, within reasonable limits, according to a predefined schedule. Second, it implies that the donor center/registry has to remove the donor from the general pool of donors for a certain period of time, in case the patient should develop a clinical situation where donation of additional cell products is warranted.
Eligibility to donate and priority
Donation of any type of cell products must never jeopardize a donor's health (beyond standard risks for the relevant cell collection) nor violate the donor's well being and autonomy. Thus, it is the donor center/registry's responsibility to ensure that the donor meets all standard health criteria, and that the requested donation does not interfere with the donor's psychological, economical, emotional, personal, moral, ethical, spiritual, and religious standards. Furthermore, the donor must be adequately insured for medical complications, disability, and accidental death relating to cell product donation. 1 Any indicators suggesting that a donor is not eligible for donation must be carefully evaluated.
Overall, the donor center/registry should concentrate on the donor's situation and rights, while the transplant center should focus on the patient's needs. To fulfill these responsibilities, the donor center/registry and the transplant center should function independently, with different staffing and location.
Further, a transplant center may request a donation that may interfere with the donor's private life and plans. The donor center/registry must never pressure a donor to cancel or rearrange important private events, and the donor center/registry should seek solutions that do not disturb the donor's private life and professional plans. Only if it is the donor's innermost and serious intention, based on unbiased and objective information by the donor center/registry and thorough evaluation by the donor, to alter significant plans to assist a patient, may the donor center/registry agree to the donor's arrangements.
Conclusions to general ethical principles
Every time a donor is to be asked to donate any type of cell product, it is the responsibility of the donor center/ registry to ensure that the donor's autonomy, well being, and needs are maintained. In addition, the donor center/ registry must ensure that the donor is properly insured. Further, the donor center/registry must provide sufficient information to ensure that the donor obtains an objective understanding. Finally, the donor center/registry must ensure that every act is in accordance with legal and moral standards, and that written informed consent is given. If the donor was recruited originally to a bone marrow donor registry, the donor should be given the option to reject any request for cell products. Alternatively, the donor, at the first time the donor is contacted by the donor center/registry, should be informed about the different kinds of cell products that may be requested later on.
Recommendations for regulation of donor commitment
The goal of the recommendation for regulation of donor commitment is to establish a uniform practice that protects Donor commitment and patient needs R Bakken et al the donor's rights as well as the patient's needs in a practical manner. Two important questions must be answered. How often can a donor be asked to donate additional cell products? How long can a donor be 'reserved' for a given patient? For purposes of this document, 'reserved' means the donor is available and active only for a given patient. A 'reserved' donor is excluded from other patient searches. However, exceptional situations may occur and a donor 'reserved' for a given patient, for instance for the event of a second stem cell donation in case of secondary graft failure, may donate whole blood or lymphocytes for another patient. This type of donation should, however, not reduce the donor's ability to meet the first patient's potential need of additional cell support, and the donation should be cleared by the first patient's transplant center.
Recruitment
When a volunteer donor is recruited into a donor registry, the donor is available for further blood sample requests that may lead to stem cell donation for any patient, irrespective of age, gender, nationality, ethnicity, or creed. A donor must not be 'reserved' for any specific patient at the time of recruitment. Furthermore, a potential donor is informed that patients are eligible for transplant/cell therapy.
Tissue collection for testing
A donor may give tissue (usually blood) samples for additional histocompatibility testing or confirmatory typing. Additional histocompatibility testing includes further HLA typing (carried out by a donor registry laboratory) to determine whether a donor is a potential match for a specific patient. Confirmatory typing is performed by a transplant center laboratory to confirm the HLA typing of the donor, as well as other testings determined by the transplant center.
The donor must always be informed about what the samples will be used for, for example, HLA typing, research, etc. The donor has to give an informed written consent.
Tissue sample donation frequency. A donor may be requested for additional tissue typing and confirmatory typing an unspecified number of times. However, the amount of blood collected for typing must not exceed a volume or frequency defined by the registry/donor center's policy or by WMDA recommendations.
Donor reservation after tissue sample donation. A donor is reserved for a given patient after donation of tissue samples. The donor center/registry must determine the appropriate time of reservation, based upon their policies and specific donor circumstances. It is important to consider the donor's private life and plans when determining the length of reservation. If the transplant center wishes to extend this period of reservation, they must submit a request explaining the reason for maintaining the donor reservation.
The transplant center is encouraged to provide confirmatory testing results and resolution as early as possible after tissue sample donation. This allows the donor to be accessed by other patients in need, as well as the donors to proceed with their personal life and plans. Donor commitment. Preferentially before confirmatory testing and not later than before stem cell donation, the transplant center should inform the donor center/registry about the protocol that will be used to treat the patient and any additional requests that may be anticipated. These requests may include platelet donation, whole blood donation, donor lymphocyte donation (DLI), or a second stem cell donation (marrow or peripheral blood stem cell donation). The donor center/registry should inform the donor about the potential for a transplant center to request additional cellular products after a stem cell donation. The donor should be given the option to fully or partially participate in the program. Further, the transplant center should be informed as early as possible and not later than at the donor information session (during workup) about the donor's or registry/donor center's decisions about the intent to participate in a full or only a part of the program. This intent does not exclude the possibility that the donor may later change mind about participation, and/or may become ineligible for further participation.
A transplant center must inform the donor center/ registry when a donor is considered a backup for stem cell donation. A backup donor is a suitable donor at CT level who may be asked to enter the workup and to donate in case the first donor becomes ineligible. Further, the transplant center must describe the circumstance that necessitates a backup donor and the timeline for reservation. Likewise, when a donor has been tested and is identified as a backup, the donor center/registry must determine the appropriate time of reservation based upon their policies and specific donor circumstances, as well as the needs of the transplant center and patient. When the donor is released as a backup donor, the donor should be informed by the donor center/registry the reason for the cancellation.
Post stem cell donation
A donor may be requested for additional cellular products after a stem cell donation. It is important to consider the frequency of an additional cellular product as well as the reservation period of a donor after initial stem cell donation, to prepare for a potential request post stem cell donation. Each donor center/registry should develop standards discussing the frequency of a cellular product donation and the reservation period between donations, in accordance with the WMDA recommendations and standards.
Stem cell and cellular product donation frequency. After the initial stem cell donation, a transplant center may request a donor to donate an additional stem cell product for the same patient, for example, in the case of graft failure. The additional stem cell product request may be quite some time after the initial stem cell donation, or may Donor commitment and patient needs R Bakken et al be an emergent situation that would necessitate an urgent donation shortly after the initial donation. In the latter situation, the donor may not yet be recovered from the initial donation. The emergent request should be handled/ reviewed by the donor center/registry medical board, and decisions should be made in accordance with the WMDA recommendations and standards. Multiple stem cell donations pose both medical and psychological implications for a given donor. A special task force (assigned by the WMDA) should review the medical implications about donor safety and product quality after multiple donations. With regard to the medical implications, this task force will make a recommendation about the maximum number of stem cell donations for a donor and time period between the intervals.
After an initial stem cell donation, the donor may be asked to donate a cellular product such as whole blood and lymphocytes for the same patient. The donor center/registry should follow national blood-transfusion standards with regard to the frequency and type of cell product donation, and/or recommendations defined by the WMDA task force. An emergent situation may require a cell product donation outside the national blood transfusion recommendations. These situations should be handled individually by the donor center/registry medical board.
Donor reservation after stem cell and cell product donation. After stem cell donation, it is recommended to reserve a donor for the patient for 2 years. Various circumstances may prolong the quarantine. During the post stem cell donation period, the donor may donate whole blood, plasma, and platelets for the public domain, according to national blood-transfusion standards. The donor center/registry should educate the donor to contact them in the event the donor -within a defined post stem cell donation period -is asked by a blood center to donate any other cell products.
A registry/donor center often has much information about HLA typing, infectious disease history, and blood typing data for a given donor, who has previously donated a stem cell product. Due to the extensive information available, a donor who has previously donated may be selected over a donor with less information. It is recommended that a donor who has already donated stem cells should not be used for donations to new patients, while other HLA-matched donors are available. If time allows, a requesting transplant center should therefore be asked to consider other potentially matched donors.
Donor withdrawal. As mentioned earlier, the donor is allowed to withdraw at any time (see the section 'Donor autonomy, integrity, and the right to participate vs right to choose volunteers'). This applies to any request for additional donations. If the donor is not able/willing to proceed or the donor center/registry wants to limit the donor's donations, the transplant center must be informed immediately.
Cell product donation and no previous stem cell donation
Anticipating new advances in transplantation, a donor may be requested for a cell product other than an initial stem cell donation. Cell product requests such as whole blood and lymphocyte donation may be requested with no previous stem cell donation. In this situation, the donor center/registry should follow the national blood transfusion regulations.
The transplant center must inform the donor center if requested blood or tissue samples are to be used for other types of testing, such as research use or for the purpose of generating cell products that may be used in any kind of cell therapy, or for other kinds of therapeutic protocols. Further, the transplant center must inform the donor center about the purpose for these requests, whether future requests are likely, and what clinical protocol it is a part of. Blood or tissue sample collection for these special purposes can only be performed with informed written donor and patient consent. This consent should be obtained as early in the process as possible, but not later than tissue sample collection for the specific research protocol.
Cell product frequency. The donor center/registry should follow national blood transfusion standards and WMDA recommendations, with regard to the frequency of cell product donation such as whole blood and lymphocyte donation. It is recognized that there may be an emergent situation that would require a cell product donation outside the national blood-transfusion recommendations. This situation should be handled separately by donor center/ registry medical board.
Cell product reservation. A donor center/registry must determine the period of time a donor remains reserved for a specific patient, following a lymphocyte or whole blood donation. Similar considerations, as listed in the section 'Donor reservation after stem cell and cell product donation', must be considered when determining the length of donor reservation. If the patient dies, the donor becomes available according to the national blood transfusion recommendations.
Cell manipulation
When a cell product will be manipulated, a donor must be informed and give written informed consent. The nature of the manipulation, for example, cryopreservation, T-cell depletion, enrichment of CD34 þ cells, establishment of antigen-specific T-cell lines or clones, etc, should be described for the donor. In addition, the amount of cells needed for these purposes must not exceed the maximum allowable limits, according to national standards and recommendations.
Cryopreservation of a whole cellular product should be approached with caution. Donor availability may prevent a cell product collection at a crucial time for a patient. For the patient, delay of the cell product collection may have significant medical and life-sustaining implications. In exceptional cases, cryopreservation of the cells may be necessary to meet the needs of both donor and patient. When a decision to cryopreserve a product is made, there is additional risk that the patient circumstances may change and the product never infused. The donor must be informed about this additional risk.
The transplant center should describe to the donor registry/ center how manipulated cell products will be used, and how they will be destroyed when outdated or not infused.
Implementation and monitoring of ethical principles
It is the responsibility of individual donor registries and donor centers to implement the principles outlined above. Since the given principles reflect WMDA standards and recommendations, a donor registry will implement these principles in its standards, working procedures, forms, etc when the registry applies for and eventually obtains WMDA accreditation. The principles are already reflected in WMDA publications, [2] [3] [4] and will be part of the requirements for WMDA accreditation. Finally, a monitoring system will be part of the program for maintaining WMDA accreditation.
